Pharma News

Six months after successfully winning U.S. Food and Drug Administration (FDA) approval for Beqvez, a gene therapy to treat hemophilia B, Pfizer is once again on the cusp of another important product indication approval.

As Roche faces increasing market competition in its breast cancer treatments, the company is eager for its new drug to breathe new life into its once-stellar portfolio and generate up to 2 billion Swiss francs in additional revenue.

Five months after Eli Lilly and Company received two important approvals in China for tizepatide -- one for type 2 diabetes and the other for obesity -- it announced plans to expand its production site in Suzhou, China.

Bayer AG (BAYGn.DE) has been ordered to pay up to $78 million in damages to a Pennsylvania man who claimed he developed a deadly form of cancer from using Bayer's Roundup herbicide.

Recently, Hengrui Medicine officially received a notice from the U.S. Food and Drug Administration (FDA) confirming that its abbreviated New Drug Application (ANDA) for paclitaxel for injection (albumin-binding) has been approved.

DKSH Healthcare, a leading partner for healthcare companies seeking to expand their business in Asia and beyond, has signed an exclusive agreement with R-Biomeds, a global pharmaceutical company headquartered in Singapore.

• DKSH
• R-Biomeds

Although the US Biosafety Act has not yet officially come into effect, its potential impact on domestic pharmaceutical companies is still significant, like a pending sword.

Genentech, a division of Roche, entered into a major agreement with Rueger, with Genentech successfully acquiring Rueger's portfolio of next-generation CDK inhibitors for $850 million in upfront cash and other potential milestone payments.

SIBUR and the biopharmaceutical company Pharmasyntez have agreed to jointly develop and supply synthetic materials for the new production facility for hemodialysis and peritoneal dialysis consumables and equipment.

• SIBUR
• Pharmasyntez

On October 9, Bayer officially announced that its New Drug Marketing Application (NDA) has been accepted by the US Food and Drug Administration (FDA).

Shares of British pharmaceutical giant GlaxoSmithKline (GSK) rose a remarkable 6.5% on Thursday after the company announced it would pay up to $2.2 billion to settle a series of lawsuits in the United States.

Ian Read, the former chief executive of Pfizer, and Frank D 'Amelio, the former chief financial officer, have made it clear that they will not be involved in a deal by activist investor Starboard Value against the company.

In a formal statement, COMCO explained in detail that the committee has been in the process of investigating the matter since September 2022.

On October 4, 2024, the European Food Safety Authority (EFSA) issued an official statement announcing plans to revise the maximum residue limits for dichloropropionic acid (MRL) in cereals.

The deep integration of experimental verification aims to lead programmable biology into a new era.

Doppler ultrasound measurement has a significant impact in medical research. The study focused on clinical data from 236 patients in Egypt, Ghana, Kenya, Nigeria, Oman, Saudi Arabia, the United States and the United Kingdom.

Edward Life Sciences has announced that 40 of its employees have been notified under a global layoff plan.

A unit of Johnson & Johnson filed for bankruptcy Wednesday for the third time, Reuters reported, aiming to advance a $10 billion settlement to end tens of thousands of lawsuits alleging the company's baby powder and other talc products may cause cancer.

Sanofi and Regeneron announced Friday that the U.S. Food and Drug Administration (FDA) has officially approved Dupixent, a new drug designed to treat patients with chronic lung disease, commonly known as "smoker's lung."

Pfizer has announced an important decision to voluntarily withdraw all approved OXBRYTA® (voxelotor) lots for the treatment of sickle cell anemia (SCD) and to suspend clinical trials of voxelotor worldwide and its expanded access program.